International Stem Cell CORP (ISCO) stock
ISCOOTCPharmaceutical PreparationsFiscal year ends December 31
$0.28+0.00 (+0.89%)
Close on Oct 19, 2026Market cap $2.27MP/E –Yield –
International Stem Cell operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
International Stem Cell's operating income for the twelve months ending Jun 30, 2026 was -$444.00K. For fiscal 2025 it was -$267.00K. The highest annual figure on record is -$68.00K in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$267.00K | – |
| FY2024 | Dec 31, 2024 | -$68.00K | – |
| FY2023 | Dec 31, 2023 | -$663.00K | – |
| FY2022 | Dec 31, 2022 | -$183.00K | – |
| FY2021 | Dec 31, 2021 | -$1.92M | – |
| FY2020 | Dec 31, 2020 | -$2.82M | – |
| FY2019 | Dec 31, 2019 | -$5.73M | – |
| FY2018 | Dec 31, 2018 | -$3.47M | – |
| FY2017 | Dec 31, 2017 | -$4.94M | – |
| FY2016 | Dec 31, 2016 | -$4.85M | – |
| FY2015 | Dec 31, 2015 | -$4.56M | – |
| FY2014 | Dec 31, 2014 | -$8.68M | – |
| FY2013 | Dec 31, 2013 | -$7.55M | – |
| FY2012 | Dec 31, 2012 | -$9.82M | – |
| FY2011 | Dec 31, 2011 | -$11.36M | – |
| FY2010 | Dec 31, 2010 | -$10.46M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$35.00K | -121.0% |
| Q1 FY2026 | Mar 31, 2026 | -$190.00K | – |
| Q4 FY2025 | Dec 31, 2025 | -$313.00K | -713.7% |
| Q3 FY2025 | Sep 30, 2025 | $94.00K | – |
| Q2 FY2025 | Jun 30, 2025 | $167.00K | +12.1% |
| Q1 FY2025 | Mar 31, 2025 | -$215.00K | – |
| Q4 FY2024 | Dec 31, 2024 | $51.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$90.00K | – |
| Q2 FY2024 | Jun 30, 2024 | $149.00K | – |
| Q1 FY2024 | Mar 31, 2024 | -$178.00K | -9000.0% |
| Q4 FY2023 | Dec 31, 2023 | -$424.00K | -795.1% |
| Q3 FY2023 | Sep 30, 2023 | -$97.00K | – |
| Q2 FY2023 | Jun 30, 2023 | -$144.00K | -564.5% |
| Q1 FY2023 | Mar 31, 2023 | $2.00K | -92.0% |
| Q4 FY2022 | Dec 31, 2022 | $61.00K | – |
| Q3 FY2022 | Sep 30, 2022 | -$300.00K | – |
| Q2 FY2022 | Jun 30, 2022 | $31.00K | – |
| Q1 FY2022 | Mar 31, 2022 | $25.00K | – |
| Q2 FY2021 | Jun 30, 2021 | -$406.00K | – |
| Q1 FY2021 | Mar 31, 2021 | -$567.00K | – |
| Q4 FY2020 | Dec 31, 2020 | -$733.00K | – |
| Q3 FY2020 | Sep 30, 2020 | -$798.00K | – |
| Q2 FY2020 | Jun 30, 2020 | -$832.00K | – |
| Q1 FY2020 | Mar 31, 2020 | -$455.00K | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.48M | – |
| Q3 FY2019 | Sep 30, 2019 | -$813.00K | – |
| Q2 FY2019 | Jun 30, 2019 | -$941.00K | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.49M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.26M | – |
| Q3 FY2018 | Sep 30, 2018 | -$663.00K | – |
| Q2 FY2018 | Jun 30, 2018 | -$367.00K | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.19M | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.92M | – |
| Q3 FY2017 | Sep 30, 2017 | -$970.00K | – |
| Q2 FY2017 | Jun 30, 2017 | -$1.00M | – |
| Q1 FY2017 | Mar 31, 2017 | -$1.05M | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.17M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.26M | – |
| Q2 FY2016 | Jun 30, 2016 | -$1.25M | – |
See a number that looks wrong?